Saffron for Depression: Better Than You Think
Saffron (Crocus sativus) is best known as an expensive cooking spice, but it is one of the most clinically supported natural antidepressants — a 2019 meta-analysis of 23 randomized trials found a large effect on depression scores (Hedges’ g around −0.99) and head-to-head equivalence with standard antidepressants like fluoxetine, with fewer side effects. The evidence is strongest in mild-to-moderate depression; severe depression has not been tested, so it is not a stand-alone treatment for severe illness, suicidal ideation, bipolar disorder, or psychosis. The trial-supported dose is 30 mg/day of a standardized extract, which you cannot get from cooking because heat destroys the active safranal and crocin and recipes use only a few threads. If you take an SSRI, MAOI, or another serotonergic drug, check with a clinician before adding it, since combining serotonergic agents carries a theoretical serotonin-syndrome risk.
The clinical evidence
The Hausenblas et al. 2013 meta-analysis (Journal of Integrative Medicine, PMID 24299602) was the first to pool the early trial data: 5 placebo-controlled and active-controlled studies showing saffron extract significantly outperformed placebo and matched fluoxetine and imipramine. Larger and more recent reviews have built on it. Marx et al. 2019 (Nutrition Reviews, PMID 31504123) pooled 23 RCTs and found saffron beat placebo by a large effect size (Hedges’ g around −0.99 for depression scores) and matched standard antidepressants head-to-head. Saffron also caused fewer side effects than SSRIs or tricyclics. These effect sizes are bigger than those of most other “mood” supplements and similar in size to the effect SSRIs show over placebo.
Head-to-head with antidepressants
How it might work
Saffron’s active compounds are safranal and crocin — the carotenoid pigments that give the spice its color and aroma. Lab studies suggest these compounds slow serotonin reuptake (similar to how SSRIs work), tone down NMDA-receptor activity, and lower oxidative stress in the brain. The multi-target action may help explain why a botanical can match single-mechanism drugs in head-to-head trials. Saffron has also been linked to higher brain-derived neurotrophic factor (BDNF), a protein associated with antidepressant response.
Dose and form
Clinical trials consistently use 30 mg/day of a saffron extract standardized to safranal — either 30 mg once daily or 15 mg twice daily. You can’t reach this dose from cooking: heat destroys most of the active compounds, and recipes use only a few threads. Standardized capsules are needed. Onset of effect in trials is usually 4–6 weeks, similar to prescription antidepressants.
Who it’s for
The current evidence supports saffron as a reasonable option for mild-to-moderate depression, especially for people who prefer a non-drug option, who had significant SSRI side effects (such as sexual dysfunction), or who can’t access psychiatric care. It is not a stand-alone treatment for severe depression, suicidal ideation, bipolar disorder, or psychosis. If you take an SSRI, MAOI, or other serotonergic medication, talk to your doctor before adding saffron — in theory, combining serotonergic agents could increase the risk of serotonin syndrome. Don’t stop a prescribed antidepressant without medical guidance.
Sources
- Hausenblas HA, et al. “Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials.” Journal of Integrative Medicine, 2013. PMID 24299602.
- Marx W, et al. “Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis.” Nutrition Reviews, 2019. PMID 31504123.
- Lopresti AL, Drummond PD. “Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action.” Human Psychopharmacology, 2014. PMID 24690614.
- Akhondzadeh S, et al. “Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression.” BMC Complementary and Alternative Medicine, 2004. PMID 15341662.
- Akhondzadeh Basti A, et al. “Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial.” Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2007. PMID 17331738.